Related Experiment Video
Updated: May 4, 2026
10:49
Intraspinal Cell Transplantation for Targeting Cervical Ventral Horn in Amyotrophic Lateral Sclerosis and Traumatic Spinal Cord Injury
Published on: September 18, 2011
20.2K
Spasticity - Pathogenesis, prevention and treatment strategies
Anju Ghai1, Nidhi Garg1, Sarla Hooda1
1Department of Anaesthesiology and Pain Medicine, Rohtak, Haryana, India.
Saudi Journal of Anaesthesia
|December 19, 2013
Summary
This review discusses long-term spasticity management for chronic disability. It emphasizes clear treatment objectives, physical therapy, and a comprehensive approach for optimal patient care.
Area of Science:
- Neurology
- Rehabilitation Medicine
Background:
- Spasticity, a consequence of nervous system injury, presents complex challenges in managing chronic disability.
- It often co-occurs with upper motor neuron syndrome, complicating rehabilitation and leading to pain, weakness, and contractures.
Purpose of the Study:
- To review long-term management strategies for spasticity in patients with chronic disability.
- To highlight clinical dilemmas and available treatment options for general practitioners.
Main Methods:
- Literature review focusing on the long-term management of spasticity.
- Analysis of clinical approaches, treatment objectives, and rehabilitation strategies.
Main Results:
- Physical treatment plays a crucial role in both the management and maintenance of spasticity.
- Optimal management requires understanding spasticity's physiology, natural history, and patient impact.
Conclusions:
- A comprehensive approach is essential to minimize the impact of spasticity on activity and participation.
- General practitioners need awareness of basic approaches and management options for this complex condition.
Keywords:
Long-term managementoutcomesperipheral nerve blockadepharmacological treatmentphenolspasticityMore Related Videos
Related Concept Videos
01:12Alterations in Muscle Tone ll
27
Alterations in muscle tone are common manifestations of neurological disorders and reflect dysfunction within different nervous system regions. Spasticity, paratonia, and dystonia represent distinct forms of hypertonia, each with unique mechanisms, clinical features, and diagnostic importance.CharacteristicsSpasticity happens from upper motor neuron lesions and is characterized by velocity-dependent resistance to passive movement. Clinical features include:Exaggerated deep tendon reflexesClonus...
27
01:29Spasmolytic Agents: Chemical Classification
1.5K
Spasmolytic agents are drugs used to alleviate muscle spasms and spasticity. They can be categorized into different chemical groups based on their mechanisms of action. Centrally acting spasmolytics primarily affect the spinal cord, while others directly target skeletal muscle cells.
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
1.5K
01:14Spinal Cord Injury ll: Pathophysiology
25
Spinal cord injury progresses through two interconnected phases: primary injury and secondary injury.Primary InjuryPrimary injury happens at the moment of trauma and involves immediate mechanical damage to the spinal cord.Compression happens when broken vertebrae, herniated discs, or accumulating blood (such as a hematoma) press directly against the spinal cord, distorting its normal shape and function. In cases of contusion, the cord is bruised by a blunt force (like penetrating injuries or...
25
01:15Parkinson's Disease: Overview
2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
01:28Classification of Skeletal Muscle Relaxants
3.6K
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
3.6K
01:25Secondary Spinal Cord Injury llI: Pathophysiology
52
Early Ischemia and Ionic ImbalanceWithin minutes of spinal cord injury, a secondary cascade begins, progressing over hours to weeks. Vascular damage reduces blood flow, causing ischemia and mitochondrial dysfunction. ATP depletion leads to ion pump failure, membrane depolarization, sodium influx, potassium efflux, and water accumulation, resulting in cellular swelling. Increased intracellular calcium further disrupts mitochondria and accelerates cellular injury.Excitotoxicity and Neuronal...
52